Indy

Market narrative

Read the headlines around the signals.

Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.

Latest prnewswire.com · about 8 hours ago

Arbe to Present at Canaccord Genuity's 46th Annual Growth Conference

TEL AVIV, Israel, Aug. 3, 2026 /PRNewswire/ -- Arbe Robotics Ltd. (NASDAQ: ARBE) (TASE: ARBE), a global leader in ultra-high-resolution radar solutions, today announced that Kobi Marenko, President, will present at and meet with investors during Canaccord Genuity's 46th Annual Growth Conference, taking place at the InterContinental in Boston on August 11-13, 2026.

Read full story ↗ Research ARBE

Stocks

More recent coverage

Page 45
SHLS globenewswire.com · about 8 hours ago

Shoals Technologies Group and TerraFlow Energy Forge Multi-Gigawatt Partnership to Advance the Future of Energy Storage

PORTLAND, Tenn., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals”) (Nasdaq: SHLS), a global leader in electrical infrastructure solutions for the energy transition market, announced a strategic Memorandum of Understanding (MOU) with TerraFlow Energy, grid-scale, long-duration energy storage infrastructure.

Read source ↗
UTZ prnewswire.com · about 8 hours ago

Unhappy With The $14.25 Per Share Buyout Price? Contact Kaskela Law to Discuss Your Legal Rights and Options with Respect to the Buyout - UTZ

PHILADELPHIA, Aug. 3, 2026 /PRNewswire/ -- Litigation firm Kaskela Law is investigating the sufficiency of the Utz Brands, Inc. (NYSE: UTZ) ("Utz") shareholder buyout proposal to determine whether Utz stockholders may be able to obtain a higher price for their shares. Additional information available at:   https://kaskelalaw.com/case/utz-buyout/ On July 21, 2026, Utz reported that it had agreed to be acquired by European snack manufacturer Intersnack Group GmbH & Co. KG ("Intersnack") at a price of $14.25 per share in cash.

Read source ↗
DSGN globenewswire.com · about 8 hours ago

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027  Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 Cash and securities of $207.4 million at quarter-end provide strong financial runway CARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported second quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio.

Read source ↗
AVBH accessnewswire.com · about 8 hours ago

Jonathan ("JD") Dale Appointed Avidbank President

SAN JOSE, CA / ACCESS Newswire / August 3, 2026 / Avidbank Holdings, Inc. (the "Company") (NASDAQ:AVBH), the holding company for Avidbank, a California state-chartered bank (the "Bank" or "Avidbank"), today announced the appointment of Jonathan M. Dale (JD) as the Bank's President, who will also serve as the Company's President, effective August 3, 2026.

Read source ↗
BDPT accessnewswire.com · about 8 hours ago

BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness Formula

Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform LAS VEGAS, NV / ACCESS Newswire / August 3, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced that the official opening of its commercial order window for XcellaraHeart™, the flagship product in the company's new Xcellara™ cellular wellness line, will take place later this week. Customers and distributors will soon be able to place orders directly through products.xcellara.com.

Read source ↗
COHN globenewswire.com · about 8 hours ago

Cohen & Company Reports Second Quarter 2026 Financial Results

Board Declares Quarterly Dividend of $0.25 per Share Revenue of $69.5 Million Net Income Attributable to Cohen & Company Inc. of $3.6 Million, or $0.94 per Diluted Share Adjusted Pre-Tax Income of $10.1 Million, or $1.62 per Diluted Share PHILADELPHIA and NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cohen & Company Inc. (NYSE American: COHN) (“Cohen & Company” or the “Company”) today reported financial results for its second quarter ended June 30, 2026. Lester Brafman, Chief Executive Officer of Cohen & Company, said, “We are pleased to deliver another solid quarter, driven by continued strong performance in our full-service boutique investment bank, Cohen & Company Capital Markets, and its expertise in SPAC and de-SPAC transactions.

Read source ↗
QSE newsfilecorp.com · about 8 hours ago

QSE Closes First Tranche of Private Placement of $5.3 Million and Announces Further Upsize to $6 Million

Vancouver, British Columbia--(Newsfile Corp. - August 3, 2026) - Quantum Secure Encryption Corp. (CSE: QSE) (OTCQB: QSEGF) (FSE: VN80) ("QSE" or the "Company") is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement financing (the "Offering", see news release dated July 10, 2026 and July 24, 2026) by issuing 11,833,456 units (the "Units") at a price of $0.45 per Unit for total proceeds of $5,325,055.20 (the "First Tranche"). Concurrent with the closing of the First Tranche and due to strong investor demand, the Company has further increased the size of the Offering.

Read source ↗
V prnewswire.com · about 8 hours ago

RTX's Raytheon completes installation of first SPY-6(V)4 array at Wallops Island test site

New radar testing will support U.S. Navy Destroyer modernization efforts  WALLOPS ISLAND, Va., Aug. 3, 2026 /PRNewswire/ -- Raytheon, an RTX (NYSE: RTX) business, has delivered and installed the first SPY-6(V)4 radar array at Surface Combat Systems Center at Wallops Island in Virginia, marking a major milestone for the U.S. Navy's Flight IIA Destroyer modernization effort and the SPY-6 backfit program.

Read source ↗
STIM globenewswire.com · about 8 hours ago

Neuronetics and Jorey Chernett Announce Shared Vision

MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics” or the “Company”) and Jorey Chernett, the Company's second largest shareholder and Managing Member of Pointillist Family Office, today announced that they have created a constructive framework for alignment between the Company's Board of Directors (the “Board”), management, and Mr. Chernett (the “Understanding”).

Read source ↗
MLAB globenewswire.com · about 8 hours ago

Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call

LAKEWOOD, Colo., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced it will release financial results for its first fiscal quarter (“1Q27”) ended June 30, 2026 following market close on Monday, August 10, 2026. The Company will also hold its first earnings conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts.

Read source ↗
EML globenewswire.com · about 8 hours ago

Swarmer and Oak Grove Technologies Announce Strategic Partnership to Advance Autonomous Drone Swarming Capabilities for U.S. Special Operations

Swarmer's battle-tested software has been integrated aboard Oak Grove's Chimera UAVs and tested extensively during recent test flights in Eastern Europe Swarmer's battle-tested software has been integrated aboard Oak Grove's Chimera UAVs and tested extensively during recent test flights in Eastern Europe

Read source ↗
AKBA globenewswire.com · about 8 hours ago

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a Phase 2 basket trial to evaluate the safety, efficacy, and pharmacokinetics of ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G).

Read source ↗
ESLA businesswire.com · about 8 hours ago

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a third clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin's lymph.

Read source ↗
P-ANTH businesswire.com · about 8 hours ago

KnowBe4 Extends Agent Security to Anthropic's Claude With Agent Risk Manager

LAS VEGAS--(BUSINESS WIRE)--Black Hat Conference - KnowBe4, the global leader in digital workforce security, securing both AI agents and humans, today announced Agent Risk Manager support for Anthropic's Claude. KnowBe4 now extends its agent governance layer to Claude environments, building on existing native support for Microsoft Copilot. With agentic AI widely integrated into daily work, 58% of cybersecurity leaders from the KnowBe4 2026 Agentic Risk to Human Wins Report state that AI agents.

Read source ↗
CHCO businesswire.com · about 8 hours ago

Archer's Midnight Completes City-to-City Flights in California Ahead of White House's eIPP

SAN JOSE, Calif.--(BUSINESS WIRE)---- $ACHR #Archer--Archer Aviation (NYSE: ACHR) today announced the completion of a piloted roundtrip journey with its all-electric Midnight aircraft on July 30th, departing from Salinas Municipal Airport and landing at Monterey Regional Airport before making the return flight. Archer worked closely with the FAA to execute this piloted, round trip inter city flight, a major step toward launching Midnight operations under the White House's eIPP program later this year. Midnight c.

Read source ↗
← Newer
Older →